HistoSonics Secures $102M in Series D Round

HistoSonics, based in Minneapolis, has successfully closed a $102 million Series D funding round. This investment marks a significant step in the company's mission to transform cancer treatment with its innovative Edison® Histotripsy System.

• Funding Leaders: The Series D round was spearheaded by Alpha Wave Ventures, with new backing from Amzak Health and HealthQuest Capital. Existing investors, including Johnson & Johnson Innovation – JJDC, Inc., Venture Investors, Lumira Ventures, and others, also participated.

• Innovative Technology: Under the leadership of Mike Blue, HistoSonics specializes in non-invasive sonic beam therapy, leveraging histotripsy. This technology uses focused ultrasound to break down and liquify unwanted tissues and tumors without invasive procedures.

• Expansion Goals: The funding will propel the commercialization of the Edison® System for liver treatment in the US and select global markets. The company is also exploring histotripsy applications for other organs, including the kidney, pancreas, prostate, and brain.

With this substantial investment, HistoSonics aims to accelerate the development of its groundbreaking non-invasive therapy and expand its impact on cancer treatment worldwide.